Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 166

1.

ISL1 is a major susceptibility gene for classic bladder exstrophy and a regulator of urinary tract development.

Zhang R, Knapp M, Suzuki K, Kajioka D, Schmidt JM, Winkler J, Yilmaz Ö, Pleschka M, Cao J, Kockum CC, Barker G, Holmdahl G, Beaman G, Keene D, Woolf AS, Cervellione RM, Cheng W, Wilkins S, Gearhart JP, Sirchia F, Di Grazia M, Ebert AK, Rösch W, Ellinger J, Jenetzky E, Zwink N, Feitz WF, Marcelis C, Schumacher J, Martinón-Torres F, Hibberd ML, Khor CC, Heilmann-Heimbach S, Barth S, Boyadjiev SA, Brusco A, Ludwig M, Newman W, Nordenskjöld A, Yamada G, Odermatt B, Reutter H.

Sci Rep. 2017 Feb 8;7:42170. doi: 10.1038/srep42170.

2.

Construction of a BioBrick™ compatible vector system for Rhodococcus.

Ellinger J, Schmidt-Dannert C.

Plasmid. 2017 Jan 24;90:1-4. doi: 10.1016/j.plasmid.2017.01.004. [Epub ahead of print]

PMID:
28130036
3.

Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear-Cell Renal-Cell Carcinoma.

Ellinger J, Poss M, Brüggemann M, Gromes A, Schmidt D, Ellinger N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC.

Clin Genitourin Cancer. 2016 Dec 1. pii: S1558-7673(16)30346-9. doi: 10.1016/j.clgc.2016.11.010. [Epub ahead of print]

PMID:
28063846
4.

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.

Uhl B, Gevensleben H, Tolkach Y, Sailer V, Majores M, Jung M, Meller S, Stein J, Ellinger J, Dietrich D, Kristiansen G.

J Mol Diagn. 2017 Jan;19(1):107-114. doi: 10.1016/j.jmoldx.2016.08.008.

PMID:
27939865
5.

Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma.

Nientiedt M, Deng M, Schmidt D, Perner S, Müller SC, Ellinger J.

Sci Rep. 2016 Nov 24;6:37158. doi: 10.1038/srep37158.

6.
7.

Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma.

Ellinger J, Gromes A, Poss M, Brüggemann M, Schmidt D, Ellinger N, Tolkach Y, Dietrich D, Kristiansen G, Müller SC.

Oncotarget. 2016 Dec 27;7(52):86490-86499. doi: 10.18632/oncotarget.13275.

8.

PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.

Gevensleben H, Holmes EE, Goltz D, Dietrich J, Sailer V, Ellinger J, Dietrich D, Kristiansen G.

Oncotarget. 2016 Nov 29;7(48):79943-79955. doi: 10.18632/oncotarget.13161.

9.

PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.

Holmes EE, Goltz D, Sailer V, Jung M, Meller S, Uhl B, Dietrich J, Röhler M, Ellinger J, Kristiansen G, Dietrich D.

Clin Epigenetics. 2016 Sep 26;8:104.

10.

CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.

Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, Stein J, Sailer V, Jung M, Kristiansen G, Dietrich D.

Epigenetics. 2016 Dec;11(12):871-880.

PMID:
27689475
11.

The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma.

Ellinger J, Gevensleben H, Müller SC, Dietrich D.

Expert Rev Mol Diagn. 2016 Oct;16(10):1059-1065.

PMID:
27649770
12.

Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients.

Ellinger J, Schneider AC, Bachmann A, Kristiansen G, Müller SC, Rogenhofer S.

Anticancer Res. 2016 Aug;36(8):3961-4.

PMID:
27466500
13.

CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.

Goltz D, Holmes EE, Gevensleben H, Sailer V, Dietrich J, Jung M, Röhler M, Meller S, Ellinger J, Kristiansen G, Dietrich D.

Oncotarget. 2016 Aug 16;7(33):53309-53320. doi: 10.18632/oncotarget.10786.

14.

Testicular seminoma clinical stage 1: treatment outcome on a routine care level.

Dieckmann KP, Dralle-Filiz I, Matthies C, Heinzelbecker J, Bedke J, Ellinger J, Anheuser P, Souchon R, Pichlmeier U; German Testicular Cancer Study Group..

J Cancer Res Clin Oncol. 2016 Jul;142(7):1599-607. doi: 10.1007/s00432-016-2162-z.

15.

Seminoma Clinical Stage 1 - Patterns of Care in Germany.

Dieckmann KP, Dralle-Filiz I, Heinzelbecker J, Matthies C, Bedke J, Ellinger J, Sommer J, Haben B, Souchon R, Anheuser P, Pichlmeier U.

Urol Int. 2016;96(4):390-8. doi: 10.1159/000443214.

16.

Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.

Syring I, Klümper N, Offermann A, Braun M, Deng M, Boehm D, Queisser A, von Mässenhausen A, Brägelmann J, Vogel W, Schmidt D, Majores M, Schindler A, Kristiansen G, Müller SC, Ellinger J, Shaikhibrahim Z, Perner S.

Oncotarget. 2016 Apr 26;7(17):23043-55. doi: 10.18632/oncotarget.8469.

17.

Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report.

Stein J, Latz S, Ellinger J, Hauser S, Sailer V, Oelmann-Avendano J, Marx C, Brossart P, Wolf D, Müller SC.

Urol Int. 2016;97(3):369-372.

PMID:
27035919
18.

Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.

Schrödter S, Braun M, Syring I, Klümper N, Deng M, Schmidt D, Perner S, Müller SC, Ellinger J.

Mol Cancer. 2016 Feb 2;15:10. doi: 10.1186/s12943-016-0495-5.

19.

NDUFA4 expression in clear cell renal cell carcinoma is predictive for cancer-specific survival.

Müller FE, Braun M, Syring I, Klümper N, Schmidt D, Perner S, Hauser S, Müller SC, Ellinger J.

Am J Cancer Res. 2015 Aug 15;5(9):2816-22.

20.

The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma.

Ellinger J, Alam J, Rothenburg J, Deng M, Schmidt D, Syring I, Miersch H, Perner S, Müller SC.

Am J Cancer Res. 2015 Aug 15;5(9):2799-807.

Items per page

Supplemental Content

Loading ...
Support Center